Mountain Valley MD Holdings Inc (CSE:MVMD, OTCQX:MVMDF) issued a new update highlighting some of the progress the company is making in the laboratory.
The firm is developing therapies and technologies for the global pharmaceutical and nutraceutical industries.
The Toronto-based company told investors that it is expanding its relationships with experts in clinical and research-focused oncology to advance its understanding of its Quicksol technology applications across a broader array of insoluble molecules that have documented anti-cancer effects from prior independent research.
READ: Mountain Valley MD enters into a letter of intent to complete a licensing agreement with Red White & Bloom Brands
It recently expanded its focus to include triple-negative breast cancer, metastatic melanoma and Lewis Lung Carcinoma after encouraging pre-clinical trial results.
Mountain Valley also said that it has started commercialization planning with local partners in Bangladesh for its injectable solubilized Ivermectin technology, Ivectosol 1%, in anticipation of all necessary government approvals for manufacturing and product distribution in 2022.
The firm has also been working with Bangladesh’s Ministry of Fisheries & Livestock on a “unique” project to evaluate the ability to administer Ivectosol 1% in a farmed fish environment to explore its potential to impact positive health outcomes.
MVMD said it has invented a novel fish food application that enables Ivectosol 1% to be delivered to fish in an aqueous environment, with the objective of helping to prevent parasitic outbreaks that cause mortality and limit healthy growth of fish.
Finally, the company said it is seeing interest in its work with its own branded ivermectin product, Ivectol, which is packaged in a 20-tablet box containing Ivermectin USP 12 milligram tablets.
Ivectol is finalizing registrations in key target markets to allow for export, as well as import and sale in approved countries, Mountain Valley said in a statement.
“We believe our science progress continues to validate the pathway we are pursuing across broad husbandry animal and human applications,” Dennis Hancock, Mountain Valley’s CEO told investors.
“I am very proud of the team and our research partners for this continuing progress across multiple lanes of innovation. We couldn’t be more honoured to drive forward this important work.”
Separately, the company said it had re-elected Dennis Hancock, Kevin Puloski, Nancy Richardson and Paul Lockhard to its board of directors and set the board at four directors, along with a host of other initiatives at its recent shareholder meeting.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas